Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe effects of Mounjaro last for roughly one week per dose. Each injection activates GIP and GLP-1 receptors for approximately seven days, which is why the treatment schedule is once weekly — the timing is built around the medicine's action, not convenience. That weekly rhythm continues for as long as treatment is clinically appropriate and reviewed; effects on appetite and weight do not persist once the medicine is stopped. Mounjaro (tirzepatide) is a prescription-only medicine requiring clinical assessment before it can be prescribed — a prescriber decides whether it is suitable for you and reviews your progress before every repeat supply.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It does, by design. Tirzepatide has a half-life of around five days, which means it remains active in the body well beyond the point of injection and keeps receptor activity elevated throughout the week. This is why how long Mounjaro lasts and how often it is taken are one and the same answer: the pharmacokinetics of the molecule set the schedule.
In practice, many people notice the appetite-suppressing effect is strongest in the two or three days after an injection and softer toward the end of the week. That is normal. It does not mean the medicine has stopped working, it reflects the natural curve of drug concentration. Some people find injecting on the same day each week, at roughly the same time, gives the most consistent experience.
A question our prescribers hear most weeks is whether it is safe to take the injection a day early if you are feeling hungry again. The short answer from the SmPC is that you should not adjust the timing yourself; if the gap between doses feels too wide, that is a conversation for your prescriber, who may consider whether a dose increase is appropriate at your next review.
The licensed starting dose of 2.5mg is a tolerability step, its purpose is to let your body adjust to the medicine, not to deliver full therapeutic effect. As your prescriber moves you up the schedule (typically in four-week steps through 5mg, 7.5mg, 10mg, 12.5mg and 15mg), both the strength and consistency of the weekly effect tend to increase.
Clinical trial data published in the New England Journal of Medicine (SURMOUNT-1) showed that average weight loss at 72 weeks reached around 20–21% at the 15mg maintenance dose, figures gathered from thousands of participants over more than a year of weekly dosing. Higher doses did not shorten the duration between injections; they increased the magnitude of effect within the same seven-day window.
If you are curious about how long Mounjaro takes to work in the first weeks of treatment, that is a separate question from duration, early weeks are about tolerability and early signals, not the full weekly rhythm you build into later in treatment.
This is the part most people want a straight answer on: the effects do not persist after stopping. Tirzepatide leaves the body gradually, and as it clears, appetite regulation returns toward baseline. For many people, that means hunger increases and the weight-loss trend slows or reverses. This is consistent with how the underlying biology works, the medicine supports a hormonal state that does not sustain itself without continued treatment.
The NHS England guidance on weight-management injections frames these medicines as long-term treatments used alongside diet and activity changes, not a short course. NICE's appraisal of tirzepatide (TA1026) reviewed evidence over 72-week trial periods, which reflects how sustained the treatment commitment needs to be to achieve and maintain results.
If stopping is planned (because of surgery, pregnancy, or a clinical decision) the prescriber at your review can advise on timing and what to expect. Pregnancy is a situation where the medicine is not recommended, and a prescriber will discuss appropriate planning. For context on what private treatment involves and its costs, the Mounjaro pricing page explains what one transparent price covers.
The weekly duration stays broadly consistent throughout treatment, but the experience of effects can shift. Some people find that after several months on a stable dose, the appetite suppression feels less dramatic, not because the medicine is working less, but because a new baseline has been established. If you want a clearer picture of how quickly you feel the effects of Mounjaro when you first start, it helps to understand that early sensations are often different from the steadier experience that settles in over subsequent months. Weight loss typically slows at a maintenance dose, which can feel like reduced effect even when the medicine is doing exactly what is expected at that point in treatment.
Tolerance, in the pharmacological sense of the body requiring ever-increasing doses to produce any effect at all, is not a documented feature of tirzepatide in clinical data. Plateau periods are normal and expected, and reading about how long it takes to feel the effects of Mounjaro can reassure people who are wondering whether their current dose is still doing its job. They are one reason ongoing clinical review matters: a prescriber can assess whether the current dose remains appropriate, whether a lifestyle adjustment could help, or whether the evidence supports continuing.
If you are thinking about whether Mounjaro is right for your situation, you can check your eligibility with a free consultation, reviewed the same day by a GPhC-registered prescriber, not software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.